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Activation of mesangial cells by platelets in systemic lupus
erythematosus via a CD154-dependent induction of CD40.
Background. Platelets are potential contributors to glomeru-
lar injury via the release of chemotactic and/or mitogenic media-
tors upon activation or through direct CD154/CD40-dependent
interaction with cell components of the glomerulus. We exam-
ined whether platelets could activate mesangial cells and the
potential role of the platelet-associated CD154.
Methods. Thrombin-activated platelets from systemic lupus
erythematosus (SLE) patients or from disease or healthy con-
trols were grown with human mesangial cells in the presence
or not of a neutralizing anti-CD154 antibody either in con-
tact or in a noncontact setting, the platelets and mesangial
cells being separated by a pore size semipermeable membrane.
The induction of mesangial cell surface antigens was assayed
by flow cytometry. The quantification of mesangial cell pro-
liferation was performed by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay and the production
of transforming growth factor-b1 (TGF-b1), platelet-derived
growth factor (PDGF) and soluble CD40 were measured by
enzyme-linked immunosorbent assay (ELISA).
Results. Activated platelets from patients with SLE could in-
duce an up-regulation of the expression of CD40 on mesangial
cells with a concomitant release of soluble CD40. This induc-
tion required a direct contact between platelets and mesangial
cells and was dependent upon the platelet-associated CD154.
Pathologic consequences of the up-regulation of CD40 were a
CD40-dependent stimulation of the proliferation of mesangial
cells and a CD40-dependent increased production of TGF-b1
by these cells.
Conclusion. Platelets from patients with SLE can activate
mesangial cells through CD40/CD154 interactions, leading to
an induction of proliferation of the mesangial cells and an en-
hanced production of TGF-b1, a profibrotic cytokine.
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Platelets are likely to participate in glomerular in-
jury in nephritis because of their role in the inflam-
matory reaction. First, platelets possess in their a
granules a large range of inflammatory mediators such as
platelet-derived growth factor (PDGF), platelet factor-4
(PF-4), regulated upon activation, normal T cell ex-
pressed and secreted (RANTES), and P-selectin, that
are released or surface-exposed after platelet activa-
tion and that are chemotactic and/or mitogenic. Sec-
ond, it has been shown that CD40 ligand (CD154) is
present within platelets and that it is transiently ex-
pressed at the platelet surface upon activation [1]. Platelet
CD154 is critical in the inflammatory reaction, acting
through the engagement of CD40. The triggering of
CD40 by CD154 on endothelial cells, for example, leads
to an up-regulation of proinflammatory cytokines, adhe-
sion molecules, reactive oxygen species, and induction
of tissue factor [1–5]. Similar links between the trigger-
ing of CD40 and the inflammatory reaction have been
described for other CD40-expressing cells [6]. Mesan-
gial cells express CD40 but little is known regarding its
functional importance, apart from the recently demon-
strated increased production of monocyte chemoattrac-
tant protein-1 (MCP-1) through the engagement of
platelet-associated CD154 [7]. Whether platelets can ac-
tivate mesangial cells via the triggering of CD40 is there-
fore an important issue because of the key role that CD40
plays in mediating several aspects of the inflammatory
reaction.
In systemic lupus erythematosus (SLE), glomerular in-
jury may be a frequent feature even in the absence of
clinical symptoms of nephritis [8]. One of the mecha-
nisms leading to glomerular injury in SLE involves the
deposition of complement-activating immune complexes
at an early stage of the disease with a major role for the
anti-double-stranded (dsDNA)-containing immune com-
plexes [8, 9].
2068
Delmas et al: Platelets activate mesangial cells in SLE 2069
There are arguments for the involvement of platelets in
the progression of glomerular injury in nephritis in gen-
eral and in SLE in particular [10, 11]. The activation of
platelets is instrumental in thrombotic microangiopathies
[12]. Several soluble platelet-derived mediators, such as
PDGF, have been implicated in renal injury and more
specifically in the activation of mesangial cells [13].
Platelet-activating factor has been proposed as a medi-
ator of renal injury [14]. Platelet-derived cationic pro-
teins were found to be associated with the glomeruli in
SLE [15] while the presence of intraglomerular capillary
thrombi has been associated with an unfavorable out-
come [8]. Platelets are frequently found to be associated
with cell components of the glomerulus or with the suben-
dothelial deposits in models of nephritis, including lupus
nephritis [15–19]. Platelet depletion led to a decrease in
glomerular cyclooxygenase and thromboxane synthase
in a model of nephrotoxic nephritis [20] and to a major
improvement of proliferative nephritis in a model of im-
mune complex injury [21]. Antiplatelet drugs have been
reported to have a beneficial effect in serum sickness
glomerulonephritis in rats [22, 23]. Therefore, platelets
may be actively involved in the pathophysiology of the
inflammatory reaction in the kidney either through the
release of proinflammatory mediators or directly by en-
gagement of specific receptors.
In this work, we found that platelets from SLE patients
could up-regulate CD40 expression on mesangial cells,
while platelets from two control groups had no effect.
We also present evidence that platelet-associated CD154
plays an essential role in this phenomenon. Furthermore,
platelets from SLE patients stimulated mesangial cell
proliferation and induced the production of transform-
ing growth factor-b1 (TGF-b1) by mesangial cells in a
CD40-dependent way.
METHODS
Patients
Twenty one SLE patients (Table 1) were included.
The study was approved by the Ethics Committee of
our institutions (Comite´ de Protection des Personnes
dans la Recherche Biome´dicale de Bordeaux 2). Patients
met at least four of the American Rheumatism Asso-
ciation (ARA) 1982 revised criteria for SLE [24]. Ex-
cept for one patient originating from Asia, all of them
were Caucasian. Clinical disease activity was scored us-
ing SLE Disease Activity Index (SLEDAI). Ten pa-
tients had active disease either at diagnosis (N = 5) or
with a disease flare defined as a minimal three-point in-
crease of the SLEDAI score compared to the last exam-
ination (N = 5). Among these, three had low platelet
counts (<100 × 109/L), three had a history of previ-
ous thrombocytopenia but were not thrombocytopenic
at the time of the study, and four never had abnormal
platelet counts during the course of the disease. Eleven
patients had quiescent disease with no variations of their
SLEDAI throughout the entire follow-up study period.
One of these patients was thrombocytopenic at the time
of the study. At the time of blood tests, some SLE
patients were being treated with oral prednisone, aza-
thioprine, and/or hydroxychloroquine. Patients with non-
SLE autoimmune conditions included three patients with
rheumatoid arthritis, two patients with sclerodermia, one
patient with Gougerot’s syndrome, and four with spondy-
larthritis. Healthy individuals from our staff were studied
as a control group (N = 20).
Antibodies
Two anti-CD154 antibodies were used: clone 2431
(Calbiochem, La Jolla, CA, USA) in blocking experi-
ments at a concentration of 2 lg/mL and clone TRAP1
(Beckman-Coulter, Marseille, France) in flow cytometry.
Anti-CD40 phycoerythrin (PE)-labeled (clone 5C3) was
from Becton-Dickinson (San Diego, CA, USA). Anti-
CD40 (clone EA-5) was from Biosource (Camarillo, CA,
USA). Goat antimouse antibody was from Beckman-
Coulter. Anti-P-selectin antibody (CD62-P) was from
Beckman-Coulter.
Recombinant human CD154 (rCD154) and other
reagents
Two rCD154 preparations were used, rCD154 with en-
hancer from Alexis Biochemicals (Coger, Paris, France)
and rCD154 from R&D Systems (Abingdon, UK). A
third preparation was obtained by transfecting COS cells
as described [4]. Quantification of rCD154 in the COS
cell supernatants was performed by enzyme-linked im-
munosorbent assay (ELISA) (R&D Systems). Recom-
binant human interferon-c (INF-c) was from Biosource.
Thrombin was from Hyphen Biomed (Neuville sur Oise,
France).
Mesangial cells
Normal renal cortex was obtained after nephrectomy
in patients with kidney tumors or from renal grafts
found to be unsuitable for transplantation according to
the criteria set out by local ethical committee. Mesan-
gial cells were obtained as previously described [25].
Briefly, glomeruli were collected by serial sieving of cor-
tex homogenates. Isolated glomeruli were digested with
type I collagenase (Sigma Chemical Co., Saint Quentin
Fallaviers, France) and collected onto an 80 lm sieve.
Glomeruli were then plated into culture dishes and grown
in a humidified 5% CO2 incubator at 37◦C in mesangial
cell culture medium composed of RPMI 1640 medium
supplemented with 10% heat-inactivated fetal calf serum
(FCS), antibiotics (100 IU/mL penicillin and 100 lg/mL
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streptomycin), sodium pyruvate, glutamine, nonessential
amino acids, and 1 mmol/L Hepes buffer. Cultures were
free of other cell types after the third to fifth passage.
This was assessed for each culture by the morphologic ap-
pearance of the cells and by immunohistochemical char-
acterization. Mesangial cells showed positive labeling for
a-smooth muscle actin (a-SMA), and negative labeling
for cytokeratin, von Willebrand factor, or smooth muscle
myosin heavy chain. Cells were used between passages
five to nine. Four different preparations each coming from
a different kidney were used.
Platelets
Whole blood was collected in the presence of inhibitors
of platelet activation (ACD tubes) (Becton-Dickinson,
Le Pont de Claix, France). Platelets were prepared as
described [26]. They were counted electronically using
a Cell-Dyn 3700 counter (Abbott Laboratories, Rungis,
France). Isolated platelets, at a concentration of 500,000
platelets/lL, were incubated in the presence or absence
of 0.5 U/lL thrombin for 5 minutes at room temperature.
Platelet activation was controlled by the expression of
P-selectin by flow cytometry.
Mesangial cell/platelet cocultures
Mesangial cells in 24-well tissue culture plates were in-
cubated in the presence of thrombin-stimulated platelets
in 1 mL mesangial cell culture medium. In some ex-
periments, platelets were separated from the mesangial
cells by a pore size semipermeable membrane (Millicell-
CM, 0.4 lm, Saint-Quentin, France). Incubation time was
48 hours. At the end of the incubation, wells were washed
twice and mesangial cells were detached by digestion with
trypsin-ethylenediaminetetraacetic acid (EDTA) then
washed before cytometry. With this protocol, contami-
nation by residual platelets was undetectable as shown
by labeling with anti-CD41 and flow cytometry analysis.
Cell proliferation assay
Four thousand mesangial cells were grown 48 hours in
96-well tissue culture plates; then 5 × 106 platelets were
added in 96-well plate in 100 lL volume, correspond-
ing to a ratio close to 500:1 platelets to mesangial cells.
A cell proliferation standard curve was established for
2000, 4000, 6000, and 8000 mesangial cells; for between
2000 and 8000 seeded cells, the standard curve was lin-
ear. After incubation, cells were washed and cell prolif-
eration was measured at either 2 or 3 days of culture with
the 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay, following the manufacturer’s in-
structions (Sigma Chemical Co.).
ELISA
Confluent (50,000) mesangial cells were grown
48 hours with 20 × 106 platelets in 24-well tissue cul-
ture paltes. Active TGF-b1 and soluble CD40 measure-
ments in cell culture supernatants were performed by
ELISA (R&D Systems) following the manufacturer’s
instructions.
Flow cytometry
Flow cytometry was performed using an EPICS XL
flow cytometer and the system II software (Coultronics,
Paris, France).
Platelet ﬂow cytometry. Platelets were fixed with 1%
paraformaldehyde at a concentration of 105/lL. For in-
direct labeling, after washing, they were incubated for 30
minutes with anti-CD154 monoclonal antibody at a con-
centration of 2 lg for 5 × 106 platelets, in a volume of 100
lL phosphate-buffered saline (PBS)/1% bovine serum al-
bumin (BSA) or isotype-matched control. Platelets were
washed once with PBS/1% BSA and further incubated
30 minutes with a 1/200 dilution of PE-labeled goat-
antimouse secondary antibody (Sigma Chemical Co.).
Mesangial cell ﬂow cytometry. For indirect labeling,
105 cells were incubated 30 minutes with anti-CD40
monoclonal antibody at a concentration of 2 lg for
5 × 105 cells, in a volume of 100 lL PBS/1% BSA.
Cells were washed once with PBS and further incubated
30 minutes with a 1/200 dilution of PE-labeled goat-
antimouse secondary antibody. For direct labeling with
fluorochrome-labeled monoclonal antibody, the second
step was omitted. Also performed were isotype-matched
controls.
Soluble CD40-Fc binding experiments
Biotinylated CD40-Fc was a kind gift from Scher-
ing Plough (Dardilly, France). For binding experiments,
platelets from SLE patients or healthy controls were ac-
tivated and fixed as above. One million platelets were
incubated with CD40-Fc at a concentration of 2.5 lg/mL
for 2 hours at room temperature. After a wash with PBS,
platelets were incubated with phycoerythrin-conjugated
streptavidin (Beckman-Coulter) for 1 hour at room tem-
perature, then washed and analyzed by flow cytometry.
Reverse transcription-polymerase chain reaction
(RT-PCR) experiments
Total RNA was prepared from mesangial cells
with a commercial kit (Masherey-Nagel, Hoerdt,
France) following the manufacturer’s recommenda-
tions. First strand DNA synthesis was performed us-
ing the RT-PCR Kit from Roche Applied Science
(Roche Diagnostics, Meylan, France) following the
manufacturer’s recommendations, starting from 2 lg
total RNA. Primers for the PCR reaction were
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5′-AAACAGACACCATCTGCAC-3′ for the forward
primer and 5′-CTACCGTTTCTCTCAGCG-3′ for the
reverse primer. These corresponded to nucleotides 358-
377 and nucleotides 862-879 for the forward and re-
verse primers, respectively, of the sequence of human
CDw40mRNA (NCBI accession # X60592). PCR con-
ditions were 45 cycles, each cycle being denaturation at
94◦C for 1 minute, annealing at 53◦C for 1 minute, and
extension for 1 minute at 72◦C. The amplified fragment
was sequenced using the ABI Prism BigDye Terminator
sequencing kit from PE Biosystems (Perkin Elmer Cor-
poration, Paris, France).
Statistics
For multiple comparisons differences among groups
were assessed using the Kruskal-Wallis test. Post hoc
pair comparisons were carried out using Bonferroni’s
adjustment.
RESULTS
We first studied the expression of CD40 on mesangial
cells. Mesangial cells expressed CD40 mRNA and the
CD40 protein was expressed on their surface membrane.
The expression of CD40 by mesangial cells was enhanced
by IFN-c and the mean fluorescence intensity (MFI) ra-
tio for CD40 expression was increased fourfold after a
48-hour stimulation by IFN-c (average of three experi-
ments) (Fig. 1). Platelets are a reservoir of CD154 that
becomes expressed at their surface following activation
by agonists that induce secretion [1, 27, 28]. We exam-
ined CD154 expression on thrombin-activated platelets
from SLE patients and two control groups represented by
healthy subjects and patients with non-SLE autoimmune
disorders. Flow cytometry showed a wide range of CD154
expression on platelets from healthy subjects or disease
controls. CD154 expression on activated platelets from
SLE patients also showed a wide range of expression be-
tween patients. No significant increase of CD154 at the
surface of activated platelets in SLE compared to dis-
ease controls or healthy subjects could be shown (Fig. 2).
Expression of P-selectin confirmed that secretion had oc-
curred but P-selectin and CD154 expression for individ-
ual patients did not correlate (data not shown).
In coculture experiments, platelets from SLE patients
or control groups were grown for a mean time of 48 hours
with mesangial cells at a ratio of 400:1. Platelets from
some SLE patients induced a strong up-regulation of
mesangial cells CD40 as shown by flow cytometry (Fig. 3).
Platelets from neither healthy subjects nor disease con-
trols increased the expression of CD40 on mesangial cells.
The induction of CD40 was observed with all prepara-
tions of mesangial cells. Contact between platelets and
mesangial cells was found to be essential for this phe-
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Fig. 1. CD40 is expressed by human mesangial cells. (A) Reverse
transcription-polymerase chain reaction (RT-PCR) experiments show-
ing the presence of CD40 mRNA in control (track 1) and interferon-
gamma (INF-c) (500 UI/mL)–induced (track 2) mesangial cells. The
identity of the amplified DNA fragment was confirmed by sequencing.
(B) Flow cytometry experiments. Basal or INF-c–induced CD40 expres-
sion on mesangial cells was measured by flow cytometry using direct or
indirect detection. Results are expressed as the mean fluorescence in-
tensity (MFI) of the test sample minus the MFI of the corresponding
isotype control (average ± SD for three experiments).
nomenon as no up-regulation of CD40 expression could
be observed when platelets and mesangial cells were sep-
arated by a membrane that prevented contact between
the cells while allowing diffusion of soluble molecules
(Fig. 3). The blocking of CD154 by a monoclonal an-
tibody prevented the induction of CD40 on mesangial
cells by platelets from SLE patients (Fig. 3). A control
irrelevant antibody had no effect on mesangial CD40.
Therefore, platelets from SLE patients specifically in-
duced an increased expression of CD40 at the surface
of the mesangial cells and this induction was contact-
and CD154-dependent. Furthermore, there was a posi-
tive correlation between the level of expression of CD154
on platelets from SLE patients and the level of the CD40
up-regulation on mesangial cells (in log MFI) (r = 0.88,
P < 0.0001). We performed binding experiments with sol-
uble CD40 to search for a possible alteration in the CD40
binding capacity of platelet associated CD154 in SLE pa-
tients and we found no differences in the binding of CD40
to either control or SLE platelets (not shown).
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Fig. 2. CD154 expression by thrombin-activated platelets from sys-
temic lupus erythematosus (SLE) patients, healthy controls, and dis-
ease controls. CD154 mean fluorescence intensity (MFI) of activated
platelets from healthy controls, disease controls, and SLE patients. Re-
sults are expressed as the ratio of the difference of the MFI of the test
sample minus the MFI of the corresponding isotype control to MFI of
corresponding isotype control (N = 17 healthy controls, N = 10 disease
controls, and N = 18 SLE patients). Top panel shows typical histogram
plots for thrombin-activated platelets from a healthy control (A) and a
SLE patient (B). Dashed line is isotype control and solid line is CD154
fluorescence.
We next examined whether the induced increased ex-
pression of CD40 on mesangial cells by platelets from
SLE patients could have consequences on the activation
of mesangial cells by studying their proliferation and their
production of active TGF-b1. The proliferation of mesan-
gial cells, as evaluated by the MTT assay, was increased
when the cells were cocultured with platelets from SLE
patients compared to healthy controls (Fig. 4). There was
no difference in the coloration of platelets alone, either
from controls or patients, by the MTT assay. The accel-
erated mesangial cell proliferation induced by platelets
from SLE patients was dependent on platelet-associated
CD154 as it was inhibited by a blocking monoclonal an-
tibody against CD154 (Fig. 4). Mesangial cells produc-
tion of active TGF-b1 was increased in the presence of
platelets from SLE patients compared to platelets from
healthy controls. This increase was also inhibited by the
blocking anti-CD154 antibody or when contact between
platelets and mesangial cells was prevented (Fig. 5). We
did not find increased TGF-b1 in the supernatants of ac-
tivated platelets from SLE patients compared to controls
(not shown). We did not observe any platelet-induced in-
crease in the production of PDGF by mesangial cells (not
shown). Finally, the up-regulation of mesangial cell CD40
by activated platelets in SLE could contribute to an en-
hanced production of soluble CD40 by mesangial cells as
soluble CD40 is proteolytically released from membrane-
bound CD40 [29, 30]. To test this hypothesis we measured
soluble CD40 in the supernatants of platelet/mesangial
cell cocultures. Results showed a strong increase in the
generation of soluble CD40 by mesangial cells in the
presence of platelets from SLE patients that were also
blocked by the neutralization of CD154 or by preventing
contact between platelets and mesangial cells (Fig. 6).
DISCUSSION
Mesangial cells expressed CD40 at their surface. This
result confirms a recent report [7]. The expression of
CD40 by mesangial cells was enhanced by IFN-c. The low
expression of CD40 by mesangial cells is therefore com-
parable for basal expression to other CD40-expressing
cells such as endothelial cells. IFN-c appears to be a con-
sistent inducer of CD40 expression in endothelial cells
[3], cells of the monocyte/macrophage lineage [31, 32],
smooth vascular cells [33] and mesangial cells [7], as in this
study. Accordingly, priming with IFN-c has been shown
to optimize the effector response to CD154 [34]. The
triggering of CD40 on CD40-expressing cells is an im-
portant mechanism in inflammation [6]. Therefore, the
up-regulation of CD40 by IFN-c may be a means by which
IFN-c causes or amplifies the inflammatory reaction. This
phenomenon may be relevant in glomerular inflamma-
tion and more specifically in lupus nephritis where IFN-c
has been shown to be a key mediator [35, 36]. However,
the potential proinflammatory consequences of CD40
triggering on mesangial cells are unclear.
The ligand for CD40, CD154, is expressed by platelets.
Platelets are a reservoir of CD154 that becomes exposed
at their surface upon activation [1, 27, 28]. Interactions
between platelet-associated CD154 and mesangial cell
CD40 could be instrumental to the inflammatory reac-
tion in glomerulonephritis. As the soluble form of CD154
has been shown to be elevated in SLE [37], we first exam-
ined the role of platelet-associated CD154 in SLE. Within
the limits of the number of patients studied, no signifi-
cant variations in the expression of CD154 on activated
platelets in SLE compared to disease controls or healthy
subjects was found. The expression of CD154 on unstimu-
lated platelets from the three groups was not significantly
different either (data not shown).
Platelet/mesangial cells cocultures showed that
thrombin-activated platelets from some SLE patients
could up-regulate the expression of CD40 at the surface
of mesangial cells. Two lines of evidence suggested
the responsibility of a direct interaction between
platelet-associated CD154 and mesangial cell CD40.
First, platelet-associated CD154 was necessary, as this
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Fig. 3. Up-regulation of mesangial cell CD40
by platelets from systemic lupus erythe-
matosus (SLE) patients via a CD40/CD154-
dependent interaction. Fifty thousand mesan-
gial cells (MC) were cocultured for 48 hours in
contact with 20 × 106 activated platelets (Plt)
from healthy controls (MC + Healthy Ctr Plt)
(N = 13) or disease controls (MC + Disease
Ctr Plt) (N = 6), or SLE patients (MC + SLE
Plt) (N = 14), in the presence or not of block-
ing anti-CD154 antibody (MC + SLE Plt +
aCD154), or in a noncontact setting, platelets
being separated from the mesangial cells by
a semipermeable membrane [MC + SLE Plt
(insert)]. Statistical significance of MC + SLE
Plt incubation compared to each other incuba-
tion is shown. Top panel shows representative
histograms. Dashed line is isotype control and
solid lines are CD154 fluorescence (gray line,
control and black line, SLE patient).
induction was inhibited by anti-CD154 blocking anti-
body. Patient to patient analysis showed that the higher
the expression of platelet-associated CD154, the higher
was the induction of mesangial CD40 and there was a
statistical correlation. The population of SLE patients
whose platelets did not induce mesangial cell CD40
corresponded to patients with low platelet-associated
CD154. Therefore, platelet-associated CD154 in SLE
patients was critical for CD40 induction on mesangial
cells. Second, separation between the platelets and the
mesangial cells prevented this induction. The lack of
CD40 induction when platelets and mesangial cells were
separated demonstrated that the soluble CD154 that
is released when platelets are activated [27, 38] was
therefore not able to induce mesangial cell CD40. This
is in agreement with the demonstration that soluble
CD154 that is released after platelet activation is not
functional to activate the endothelial cells [38]. This
may be because the soluble species is not in the right
oligomeric conformation to efficiently trigger CD40
signalling. By using different rCD154 preparations we
were also unable to observe any up-regulation of CD40
on mesangial cells. Looking for potential mechanisms,
we first found no differences in the binding of CD40 to
platelets from either control or SLE patients, suggesting
no functional alteration of platelet-associated CD154
in SLE. Experiments with combinations of rCD154
and supernatants of activated platelets or plasma from
control and SLE patients could also not reproduce the
effects of the SLE platelets (not shown). Therefore,
platelet-associated CD154 was necessary for the up-
regulation of CD40 but it may be not sufficient and an
additional costimulatory signal specifically provided by
the platelet membrane from SLE patients rather than
by a soluble-derived signal could be involved. Such
an additional costimulatory signal could possibly be a
platelet membrane protein augmenting the adhesion
of the patient’s platelets to mesangial cells. Preliminary
experiments showed no enhanced adhesion of SLE
platelets to mesangial cells when tested after 48 hours
of coculture. However, it would be interesting to test
for a possible alteration in the adhesion of SLE patients
platelets at earlier time-points. Tanaka et al [7] showed
that normal thrombin-activated platelets stimulate in
a CD154-dependent way the production of MCP-1 by
mesangial cells. In their study, rCD154 did not induce
MCP-1 unless associated with IFN-c, confirming lack of
activity of rCD154 on mesangial cells, maybe because
of the low basal expression of CD40 on mesangial
cells. As in our study, contact between platelets and
mesangial cells was essential. However, our data indicate
that the induction of CD40 required an additional
platelet-associated cofactor and studies are ongoing to
try to identify this cofactor.
CD154 is barely detectable on nonactivated platelets
[1, 27, 28, 39]. Therefore, any potential relevant effect
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Fig. 4. Activated platelets from systemic lupus erythematosus (SLE)
patients induce mesangial cell proliferation through a CD40/CD154-
dependent interaction. Mesangial cells (MC) were cocultured for
48 hours in contact with activated platelets from control (Healthy Ctr
Plt) (N = 3) or platelets from SLE patients (SLE Plt) (N = 6), as
described in the Methods section in the presence or not of blocking
anti-CD154 antibody (aCD154). Mesangial cell proliferation was mea-
sured by 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay. Results are expressed as the average optical density ±
SD, normalized to the optical density for mesangial cell control wells.
Results are also shown for mesangial cells incubated with thrombin.
Statistical significance of the results for the MC + SLE Plt incubation
compared to the other incubations is shown.
involving platelet-associated CD154 would require acti-
vation of platelets. Platelets may be activated locally in
the glomerulus following the production of platelet ago-
nists by mesangial cell or endothelial cell such as platelet
activating factor [19, 40], or because accessibility to the
subendothelium during inflammation [17]. Coagulation
and fibrinolysis are also involved in the pathogenesis of
nephritis and the extent of fibrin deposition is a clas-
sic marker of disease activity [41–43]. The generation of
thrombin will in turn activate the platelets. Accordingly,
previous reports have shown that platelets can be found
within the glomerulus in various nephropathies such as
lupus nephritis and that there is a link between platelets
and renal lesions in SLE [10, 11, 44]. Second, there is
evidence for in vivo systemic platelet activation in SLE
[18, 45, 46]. However, the mechanism for this systemic
activation is not clear, a consequence of which would
be circulating platelets expressing CD154. Notwithstand-
ing, platelets activated systemically or locally, appear to
trigger the increased expression of CD40 at the surface
of mesangial cells in a CD154-dependent way. In phys-
iologic conditions, protrusions from mesangial cells can
project into the capillary lumen or insert between the
basement membrane and the overlying endothelium [47]
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Fig. 5. Production of active transforming growth factor-b1 (TGF-b1)
by mesangial cells is significantly increased by platelets from systemic
lupus erythematosus (SLE) patients in a CD154-dependent way. A total
of 50,000 mesangial cells (MC) were cocultured 48 hours in contact with
20 × 106 activated platelets from control (Healthy Ctr Plt) (N = 3) or
platelets from SLE patients (SLE Plt) (N = 9) in the presence or not of
blocking anti-CD154 antibody (aCD154). Enzyme-linked immunosor-
bent assay (ELISA) measurements of the active form of TGF-b1 were
made on cell culture supernatants. Statistical significance of the MC +
SLE Plt incubation compared to each other incubation is shown.
rendering contact possible with platelets either directly
or through fenestrae through the endothelium. In the in-
flammatory kidney, increased vascular permeability al-
lowing blood cell elements to colonize the mesangium is
occurring through the chemotactic action of inflamma-
tory mediators. This is illustrated by the infiltration of the
mesangium by myelomonocytic cells in human nephri-
tis [48, 49] or in animal nephritis models [50, 51]. Also,
platelets are attracted by chemotactic signals to the site
of inflammation [52]. Therefore, a direct contact between
platelets and mesangial cells is most likely to occur in the
inflammatory mesangium.
Two observations from our work suggest how activated
platelets from SLE patients may activate mesangial cells
and could be instrumental in the initiation or perpetua-
tion of the glomerular injury. First, the proliferation of
mesangial cells was significantly stimulated by platelets
from SLE patients and also in a CD154-dependent way.
Mesangial cell proliferation is a key pathogenic factor
in the glomerular injury in SLE and the intensity of this
proliferation is correlated with unfavorable clinical out-
come [8]. Second, the production of active TGF-b1 by
mesangial cells was significantly increased by platelets
from SLE patients in a CD154-dependent way. TGF-b1
controls extracellular matrix production and is implicated
in glomerulosclerosis [53–55]. Platelets could therefore
be involved in mesangial cell activation in SLE via the
CD154-dependent induction of both mesangial cell pro-
liferation and TGF-b1 synthesis.
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Fig. 6. Generation of soluble CD40 by mesangial cells in the presence
of platelets from systemic lupus erythematosus (SLE) patients. A to-
tal of 50,000 mesangial cells (MC) were cocultured 48 hours in con-
tact with 20 × 106 activated platelets from control (Healthy Ctr Plt)
(N = 3) or platelets from SLE patients (SLE Plt) (N = 7) in the pres-
ence or not of blocking anti-CD154 antibody (aCD154) or in a non-
contact setting, platelets being separated from the mesangial cells by
a semipermeable membrane (insert). Enzyme-linked immunosorbent
assay (ELISA) measurements of the soluble CD40 were made on cell
culture supernatants. MC + SLE Plt compared to MC + thrombin or
MC + healthy Ctr Plt, or SLE Plt + aCD154, or MC + SLE Plt (insert),
statistical significance, P < 0.0001 for each comparison.
The up-regulation of mesangial cell CD40 could con-
tribute to an increased production of soluble CD40. The
magnitude of this increase paralleled the flow cytometry
results on the induction of CD40. Interestingly, it has been
reported that patients with end-stage renal diseases have
increased plasma levels of soluble CD40 [56, 57]. The
origin of this increase was linked to chronic renal fail-
ure but our study suggest that, at least in SLE, mesangial
cell production of soluble CD40 could be a contributing
factor. Finally, our in vitro data can adequately explain
the elevation of CD40 that has been observed in vivo in
the glomeruli of SLE patients by histochemical studies;
CD40 expression being increased on mesangial cells in
World Health Organization (WHO) SLE class III and
class IV glomerulonephritis [58, 59]. An important point
will be to search for a possible correlation between the
induction of mesangial CD40 and the development of a
clinical nephritis. We have started this study that will re-
quire a long-term follow-up of the patients.
CONCLUSION
Results from our study emphasize the role that
platelets may play in the activation of mesangial cells
in SLE. Thrombin-activated platelets from healthy sub-
jects stimulate the production of the chemokine MCP-1
by human mesangial cells through CD40/CD154 interac-
tions [7] and the cross-linking of CD40 on human renal
proximal tubular epithelial cells stimulates the produc-
tion of the chemokines interleukin (IL)-8, MCP-1, and
RANTES [60]. Therefore, the expression of CD40 in the
kidney appears to be an important means for the induc-
tion and the perpetuation of the inflammatory reaction
in glomerular or tubular diseases. Importantly, treatment
with anti-CD154 antibody reduced glomerular inflamma-
tion and sclerosis and the severity of nephritis in murine
models of lupus nephritis [61, 62]. The renoprotective ef-
fect of blocking the CD40/CD154 interactions may be
the consequence, at least in part, of the local blocking of
the interactions between platelet-associated CD154 and
mesangial cell CD40. As a key proinflammatory stimu-
lus, platelet-associated CD154 may be an active factor
in promoting the development of glomerular injury in
glomerulonephritis and in SLE as studied here.
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